T1	Participants 76 114	patients with hematologic malignancies
T2	Participants 219 257	patients with hematologic malignancies
T3	Participants 325 397	Seventy immunocompromised febrile patients with hematologic malignancies
T4	Participants 1635 1673	patients with hematologic malignancies
T5	Participants 1714 1734	high-risk population
